TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bằng De Laere, Bram, Oeyen, Steffi, Mayrhofer, Markus, Whitington, Tom, van Dam, Pieter-Jan, Van Oyen, Peter, Ghysel, Christophe, Ampe, Jozef, Ost, Piet, Demey, Wim, Hoekx, Lucien, Schrijvers, Dirk, Brouwers, Barbara, Lybaert, Willem, Everaert, Els, De Maeseneer, Daan, Strijbos, Michiel, Bols, Alain, Fransis, Karen, Beije, Nick, de Kruijff, Inge, van Dam, Valerie, Brouwer, Anja, Goossens, Dirk, Heyrman, Lien, Van den Eynden, Gert, Rutten, Annemie, Del Favero, Jurgen, Rantalainen, Mattias, Rajan, Prabhakar, Sleijfer, Stefan, Ullén, Anders, Yachnin, Jeffrey, Grönberg, Henrik, Van Laere, Steven, Lindberg, Johan, Dirix, Luc
Xuất bản năm Clin Cancer Res (2018)